Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in non-small cell lung cancer.

Intergenic-breakpoint fusions detected by DNA sequencing confound kinase fusion detection in NSCLC, as functional fusion transcripts may be generated or not. Additional validation testing using RNA/protein assay should be performed in intergenic-breakpoint fusion cases to guide optimal treatment.